Icon

OLUMIANT (nda207924)- (1MG,2MG,4MG)

BARICITINIB ELI LILLY AND CO
1MG,2MG,4MG
Yes No
2033-Mar-29 2023-May-31
None None
None No
OLUMIANT® is a Janus kinase (JAK) inhibitor indicated for: • the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. • the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO.
1 0 0
Total Other Developers 9
Drugs with Suitability No
1MG ** ** - - -
2MG ** ** - - -
4MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.